8 studies found for:    A randomized, double-blind, placebo-controlled phase III study of regorafenib
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Placebo;   Drug: Best supportive care
2 Active, not recruiting
Has Results
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Placebo
3 Active, not recruiting Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Condition: Colorectal Neoplasms
Interventions: Drug: Regorafenib (BAY73-4506);   Drug: Placebo
4 Recruiting Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Regorafenib (BAY73-4506);   Drug: Placebo
5 Recruiting Regorafenib as Adjuvant Therapy for Colorectal Cancer (CRC) With Resected Liver Metastases
Condition: Colorectal Neoplasms
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Placebo
6 Recruiting Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
Condition: Metastatic Colorectal Cancer
Intervention: Drug: Regorafenib
7 Withdrawn Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Regorafenib/FOLFOX;   Drug: Placebo/FOLFOX
8 Not yet recruiting A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Conditions: Liposarcoma;   Osteogenic Sarcoma;   Ewing/Ewing-like Sarcoma
Interventions: Drug: Regorafenib;   Drug: Placebo

Indicates status has not been verified in more than two years